The Clinical Study Of The Regimen Of CHOP Plus Rituximabin In The Treatment Of Aggressive Non-Hodgkin's Lymphoma

Objective The Aggressive B-cell Non-Hodgkin′s Lymphoma is poor with a shorten survival after conventional second-line chemotherapy. Rituximab is a chemric anti-CD20 antigen in combination with CHOP or CHOP-like chemotherapy may improve both disease-freely survival and overall survival of na?ve patients. .This study was to evaluate the efficacy of the regimen of CHOP(cyclophosphamide epirubicin vincristine prednisone)Plus Rituximab successfully in the primary Treatment of Aggressive Non-Hodgkin′s Lymphoma. Methods The clinical data of 27 patients were collected department of Hematology People's Hospital of xinjing uyger autonomous region with Primary Treatment of Aggressive Non-Hodgkin′s Lymphoma were divided in to two groups :treatment group (n=13) and control group(n=14).The patients in treatment group were treated with the regimen of CHOP and Rituximab ,and the patients in control group were treated with the regimen of CHOP. Results In the treatment group,the overall complete remission rate was 76.9%(10/13), partly remission rate was 15.4%(2/13); stability diseases rate was7.7%(1/13) the mean remission time was 14.9±2.7 months ;and in the control group ,the overall complete remission rate was 35.7%(5/14), the partly remission rate was 21.4%(3/14); stability diseases rate was22.6%(4/14) the progressive disease rate was14.3%(2/14) ,the mean remission time was 3 6±2 1months.The difference of the efficacy in the two groups is significant (P<0 05). there was no significant difference between the adverse reaction rate of two groups. Conclusion In the treatment to The Primary Treatment of Aggressive Non-Hodgkin′s Lymphoma , the regimen of CHOP combined with Rituximab is more effective than the regimen of CHOP. there was no significant difference between the adverse reaction rate of two groups.